What Frontline Treatment Should Be Used in Advanced Ovarian Cancer?

<p><span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;">Dr. Linda Duska and Dr. Kathleen Moore discuss key studies in the evolving controversy over radical upfront surgery versus neoadjuvant chemotherapy in advanced ovarian cancer.</span></p> <p><span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;"><span style="text-decoration: underline;"> <strong>TRANSCRIPT</strong></span></span></p> <p class="MsoNormal"><span style= "font-size: 12pt; font-family: arial, helvetica, sans-serif;"><strong> Dr. Linda Duska:</strong> Hello, and welcome to the <em>ASCO Daily News</em> Podcast. I am your guest host, Dr. Linda Duska. I am a professor of obstetrics and gynecology at the University of Virginia School of Medicine. </span></p> <p class="MsoNormal"><span style= "font-family: arial, helvetica, sans-serif; font-size: 12pt;">On today's episode, we will explore the management of advanced ovarian cancer, specifically with respect to a question that has really...